stockportfolio.pro
Stocks / MESO vs OMCL
MESO vs OMCL
Mesoblast Limited and Omnicell, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Mesoblast Limited (MESO) | Omnicell, Inc. (OMCL) | |
|---|---|---|
| Market cap | $1.8B | $1.7B |
| Revenue (latest FY) | $17.20M | $1.18B |
| Net income (latest FY) | $-102.14M | $2.05M |
| Revenue growth (5y CAGR) | 19.0% | 5.8% |
| Net margin | -593.9% | 0.2% |
| Return on equity | -17.1% | 0.2% |
| P/E ratio | — | 87.3 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MESO — free Open OMCL — freeFrequently asked questions
Which is bigger, MESO or OMCL?
Mesoblast Limited is larger by market capitalization — $1.8B versus $1.7B.
Which grows faster, MESO or OMCL?
Over the last five fiscal years, Mesoblast Limited grew revenue faster — 19.0%/yr versus 5.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.